Selective cdk7 inhibitor (IC50
= 21 nM). Displays >40-fold selectivity for cdk7 over others cdks. Promotes cell cycle arrest and apoptosis in a range of cancer cells in vitro
and inhibits MCF-7 tumor xenograft growth in mice.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity.
Ali et al.
Cancer Res., 2009;69:6208